JAK2 and acute lymphoblastic leukemia: Consistent with the effects of ruxolitinib on B-ALL cell proliferation, JAK2 knockdown did not induce apoptosis (Fig. 1D,I), and competitive growth assays demonstrated a loss of representation of JAK2-depleted MHH-CALL4 cells evident after >8 d (Fig. 1E).